HIV Infection and Osteoporosis: Pathophysiology, Diagnosis, and Treatment Options

被引：22

作者：

Rothman, Micol S. ^{[1
]}

Bessesen, Mary T. ^{[2
,3
]}

机构：

[1] Univ Colorado Sch Med, Dept Med Endocrinol Diabet & Metab, Aurora, CO 80045 USA

[2] Eastern Colorado Healthcare Syst, Dept Vet Affairs, Denver, CO 80220 USA

[3] Univ Colorado Sch Med, Div Infect Dis, Dept Med, Aurora, CO 80045 USA

来源：

CURRENT OSTEOPOROSIS REPORTS | 2012年 / 10卷 / 04期

关键词：

HIV infection; Osteoporosis; Bone density; Fracture; HAART; BONE-MINERAL DENSITY; ANTIRETROVIRAL THERAPY; PROTEASE INHIBITORS; ABACAVIR-LAMIVUDINE; RISK-FACTORS; VITAMIN-D; T-CELLS; ZOLEDRONATE; PREVALENCE; INITIATION;

D O I：

10.1007/s11914-012-0125-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

As the population with HIV continues to age, specialists in HIV care are increasingly encountering chronic health conditions, which now include osteoporosis, osteopenia, and fragility fractures. The pathophysiology of the bone effects of HIV infection is complex and includes traditional risk factors for bone loss as well as specific effects due to the virus itself, chronic inflammation, and HAART. Examining risk factors for low bone density and screening of certain patients is suggested, and consideration should be given to treatment for those considered high risk for fracture.

引用

页码：270 / 277

页数：8

共 37 条

[1] HIV and bone loss [J].

Arora S. ;

Agrawal M. ;

Sun L. ;

Duffoo F. ;

Zaidi M. ;

Iqbal J. .

Current Osteoporosis Reports, 2010, 8 (4) :219-226

[2] Annual zoledronate increases bone density in highly active Antiretroviral therapy-treated human immunodeficiency virus-infected men: A randomized controlled trial [J].

Bolland, Mark J. ;

Grey, Andrew B. ;

Horne, Anne M. ;

Briggs, Simon E. ;

Thomas, Mark G. ;

Ellis-Pegler, Rod B. ;

Woodhouse, Andrew F. ;

Gamble, Greg D. ;

Reid, Ian R. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (04) :1283-1288

[3] Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least Five Years in HIV-Infected Men [J].

Bolland, Mark J. ;

Grey, Andrew ;

Horne, Anne M. ;

Briggs, Simon E. ;

Thomas, Mark G. ;

Ellis-Pegler, Rod B. ;

Gamble, Greg D. ;

Reid, Ian R. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (06) :1922-1928

[4] Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review [J].

Brown, Todd T. ;

Qaqish, Roula B. .

AIDS, 2006, 20 (17) :2165-2174

[5] Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens [J].

Brown, Todd T. ;

Ross, Allison C. ;

Storer, Norma ;

Labbato, Danielle ;

McComsey, Grace A. .

ANTIVIRAL THERAPY, 2011, 16 (07) :1063-1072

[6]

Brown TT, 2010, ANTIVIR THER, V15, P425, DOI [10.3851/IMP15021, 10.3851/IMP1502]

[7] Reduced bone mineral density in HIV-infected patients:: prevalence and associated factors [J].

Cazanave, Charles ;

Dupon, Michel ;

Lavignolle-Aurillac, Valerie ;

Barthe, Nicole ;

Lawson-Ayayi, Sylvie ;

Mehsen, Nadia ;

Mercie, Patrick ;

Morlat, Phillipe ;

Thiebaut, Rodolphe ;

Dabis, Francois .

AIDS, 2008, 22 (03) :395-402

[8] Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults [J].

Collin, Fideline ;

Duval, Xavier ;

Le Moing, Vincent ;

Piroth, Lionel ;

Al Kaied, Firas ;

Massip, Patrice ;

Villes, Virginie ;

Chene, Genevieve ;

Raffi, Francois .

AIDS, 2009, 23 (08) :1021-1024

[9] Therapeutic Options for Low Bone Mineral Density in HIV-Infected Subjects [J].

Cotter, Aoife G. ;

Mallon, Patrick W. G. .

CURRENT HIV/AIDS REPORTS, 2012, 9 (02) :148-159

[10] Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy [J].

Curran, Adrian ;

Martinez, Esteban ;

Saumoy, Maria ;

del Rio, Luis ;

Crespo, Manuel ;

Larrousse, Maria ;

Podzamczer, Daniel ;

Burgos, Joaquin ;

Lonca, Montse ;

Domingo, Pere ;

Maria Gatell, Jose ;

Ribera, Esteban .

AIDS, 2012, 26 (04) :475-481

← 1 2 3 4 →